We are live on ! Find out more
SWTX

SpringWorks Therapeutics

Delisted

SWTX was delisted on the 30th of June, 2025.

147 hedge funds and large institutions have $1.58B invested in SpringWorks Therapeutics in 2023 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 54 increasing their positions, 48 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

55% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 11

13% more repeat investments, than reductions

Existing positions increased: 54 | Existing positions reduced: 48

4% more funds holding

Funds holding: 142147 (+5)

1.96% less ownership

Funds ownership: 111.38%109.42% (-2%)

13% less capital invested

Capital invested by funds: $1.82B → $1.58B (-$242M)

20% less funds holding in top 10

Funds holding in top 10: 54 (-1)

43% less call options, than puts

Call options by funds: $256K | Put options by funds: $453K

Holders
147
Holders Change
+5
Holders Change %
+3.52%
% of All Funds
2.33%
Holding in Top 10
4
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-20%
% of All Funds
0.06%
New
17
Increased
54
Reduced
48
Closed
11
Calls
$256K
Puts
$453K
Net Calls
-$197K
Net Calls Change
+$47K
Name Holding Trade Value Shares
Change
Change in
Stake
Millennium Management
51
Millennium Management
New York
$2.66M +$3.14M +114,923 New
Russell Investments Group
52
Russell Investments Group
United Kingdom
$2.54M +$331K +12,106 +12%
D.E. Shaw & Co
53
D.E. Shaw & Co
New York
$2.44M -$1.76M -64,311 -38%
Barclays
54
Barclays
United Kingdom
$2.26M -$652K -23,844 -20%
UOC
55
UBS O'Connor
Illinois
$2.16M -$612K -22,397 -19%
RhumbLine Advisers
56
RhumbLine Advisers
Massachusetts
$2M +$174K +6,345 +8%
Manulife (Manufacturers Life Insurance)
57
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$1.98M +$283K +10,359 +14%
Citigroup
58
Citigroup
New York
$1.84M -$231K -8,458 -10%
Swiss National Bank
59
Swiss National Bank
Switzerland
$1.75M +$19.1K +700 +0.9%
Voloridge Investment Management
60
Voloridge Investment Management
Florida
$1.72M -$3.22M -117,747 -61%
AllianceBernstein
61
AllianceBernstein
Tennessee
$1.53M
Envestnet Asset Management
62
Envestnet Asset Management
Illinois
$1.42M +$1.09M +39,902 +186%
UBS AM
63
UBS AM
Illinois
$1.27M +$337K +12,336 +29%
Two Sigma Investments
64
Two Sigma Investments
New York
$1.2M -$57.4K -2,100 -4%
Balyasny Asset Management
65
Balyasny Asset Management
Illinois
$1.09M +$1.29M +47,218 New
Royal Bank of Canada
66
Royal Bank of Canada
Ontario, Canada
$1.08M +$127K +4,659 +11%
AA
67
ALPS Advisors
Colorado
$1.07M +$6.92K +253 +0.6%
California State Teachers Retirement System (CalSTRS)
68
California State Teachers Retirement System (CalSTRS)
California
$1,000K -$175K -6,393 -13%
VOYA Investment Management
69
VOYA Investment Management
Georgia
$970K +$6.37K +233 +0.6%
AAA
70
Affinity Asset Advisors
New York
$961K -$2.42M -88,419 -68%
Victory Capital Management
71
Victory Capital Management
Texas
$953K +$1.13M +41,240 New
Susquehanna International Group
72
Susquehanna International Group
Pennsylvania
$930K -$92.8K -3,395 -8%
Macquarie Group
73
Macquarie Group
Australia
$905K +$20.9K +764 +2%
BFM
74
Boothbay Fund Management
New York
$889K +$1.05M +38,447 New
Jane Street
75
Jane Street
New York
$883K -$5.59M -204,558 -84%

SWTX Hedge Fund Activity: Q3 2023 in Review

147 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in SpringWorks Therapeutics (SWTX) for Q3 2023, worth a combined $1.58B — down 13% from $1.82B a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new SWTX positions and 11 closed out — a net gain of 6 holders — while 54 added to existing stakes and 48 trimmed.

The largest buyer was Maverick Capital, opening a new position worth an estimated $17.4M. The largest seller was Bank of America, cutting an estimated $29.6M.

  • 147 institutional investors held SpringWorks Therapeutics (SWTX) as of Q3 2023, up from 142 in Q2 2023.
  • Funds reported $1.58B of SpringWorks Therapeutics stock for Q3 2023, down 13% quarter-over-quarter.
  • 17 funds opened new SpringWorks Therapeutics positions in Q3 2023 and 11 closed out, a net change of +6 holders.
  • The largest SpringWorks Therapeutics buyer in Q3 2023 was Maverick Capital, an estimated $17.4M added.
  • The largest SpringWorks Therapeutics seller in Q3 2023 was Bank of America, an estimated $29.6M sold.

Based on aggregated 13F filings for Q3 2023.